Skip to main content

Bacteriophage: Mr. Nice Guys of the Virus World

 It's widely accepted that HIV, Hepatitis C, Ebola, and the ongoing coronavirus have acquired a bad reputation for viruses due to their aggressive and infectious nature. But actually, there are nice guys in the virology world, microscopic bacteriophages. Different from dreadful bad viruses that will invade the host cell to take over the cellular machinery, release more infectious viral particles, and finally cause illness, phages are protective viruses that can attack and destroy bacteria.

 

About Phages

 

Bacteriophage, or known as phage, whose name is derived from the Greek word phagein, indicating the eater of bacteria. These spidery-looking viruses have a population of over 1031, larger than the total number of all other organisms, including bacteria, remaining the most abundant life-form on the planet. They could be found almost everywhere bacteria exist, including water, air, soil, the mucous membrane lining of digestive, respiratory, and reproductive tracts in bodies.

 

Phages are generally classified into virulent and temperate phages according to whether they cause host cell lysis. Virulent phages kill bacteria by infecting bacteria and lysing host cells, while the temperate bacteriophages integrate genes into bacterial DNA, which will synchronously replicate with hosts' DNA without causing cell lysis.

 

Bacteriophages As Therapy

 

With the powerful nature of killing bacteria and the undeniable fact that antibiotic-resistant infections are increasingly causing deaths, phages are chosen as the potential anti-bacterial therapies.

 

Compared to antibiotic treatments, bacteriophage therapy represents more excellence in different aspects. One obvious upside to phage therapy is that no obvious side effect is observed in the patients. Different from antibiotics that work on all bacteria, including the good ones, phages only attack a specific type or group of bacteria. Besides, phage-based therapies do not depend on dosage so much.

 

Although bacteria will also develop resistance to phages to survive, it takes less time to develop new phage therapies than novel antibiotic development. Moreover, the biological nature of phages enables them to evolve along with bacteria if they adjust to escape from the phages.

 

Phages have been allowed to treat dysentery, sepsis caused by Staphylococcus aureus, salmonella infections, and skin infections in some European and Asia countries and are approved by the FDA and USDA in the USA for treating processed poultry and meat products.

 

The Future of Phages

 

Public usage of phages as therapeutics still is an open case due to lack of research. However, it's undeniable that both unmodified and engineered phages keep attracting researchers in various fields. For instance, researchers use phage display to modify and isolate antibodies for in vitro and in vivo diagnostic and therapeutic purposes. Furthermore, phage or phage display vaccines could contribute to treating bacterial and viral pathogens, as well as cancer diseases. To sum up, bacteriophages are the Mr. nice guys in the virus world in the forms of reporter phages, labeled phages, therapeutic phages, etc.

Comments

Popular posts from this blog

Everything You Want to Know About Antibody Development

  Everything You Want to Know About Antibody Development   When foreign molecules, which are known as antigens, enter our body, antibodies will be released by B cells of the immune system to specifically bind to the antigens and finally clear out those “invaders”. Such a highly specific molecular recognition mechanism has inspired a variety of antibody development research and diagnostic applications nowadays, including IVD antibody development .   What is Antibody Development?   Antibody development is the process of creating and characterizing an antibody.   The timeline of developing antibodies starts from the injection of an antigen of interest into a host animal, so that the host’s immune system can detect it and generat e  the desired antibodies. Then, antibody development proceeds with finding and isolating the desired antibodies from the rest of the protein in sera.   The reset procedure of antibody development is varied as the desired antibodi...

An Overview of the Global Bispecific Antibody Therapeutics Market

  Antibod ies , a major component of adaptive immunity, play a critical role in protective and pathogenic immune responses. In r ecent years, a wide range of antibodies is discovered as candidates of cancer therapeutic agents, including the reconstructive molecules, bispecific antibodies (BsAbs).   About Bispecific Antibody   Bispecific antibodies, as its name indicates, consists of two antigen-binding sites, which can simultaneously bind two separate and unique antigens (or different epitopes of the same antigen). This structure is  typically designed to bind to two targets, one on a cancer cell and one on an immune cell, act ivating or redirecting immune effector cells with the goal of getting the immune cell to kill the cancer cell by antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and other cytotoxic mechanisms.   U nique biological and pharmacological properties, ...

Unmodified Bacteriophages Research Updates

  R ecent research conducted by researchers from Yale University is published in  Applied and Environmental Microbiology , suggesting  that natural bacteriophage, or phage, can kill dysentery-causing bacteria and reduce virulence in surviving bacteria. It's a piece   of  inspiring news as  treating dysentery has become a challenge with the rising antibiotic resistance.   Background   Shigella flexneri , the culprit causing contagious infection marked by inflammatory diarrhea and dysentery in sub-Saharan Africa and southern Asia, kills about 160,000 people globally every year. The World Health Organization (WHO) takes priority to this pathogen in terms of increasing cases, antimicrobial resistance, and limited treatment options.   S. flexneri  is active primarily in low-income countries, like southern Asia and sub-Saharan Africa. In these places, dirty drinking water is a concern causing dysentery, while antibiotics are expensive and unav...